Microglial ERK-NRBP1-CREB-BDNF signaling in sustained antidepressant actions of (R)-ketamine
Open accessThe DOI matches its Crossref record; 80 of the 80 references it cites were found in a registry or an index.
Abstract
(R,S)-ketamine elicits rapid-acting and sustained antidepressant actions in treatment-resistant patients with depression. (R)-ketamine produces longer-lasting antidepressant effects than (S)-ketamine in rodents; however, the precise molecular mechanisms underlying antidepressant actions of (R)-ketamine remain unknown. Using isobaric Tag for Relative and Absolute Quantification, we identified nuclear receptor-binding protein 1 (NRBP1) that could contribute to different antidepressant-like effects of the two enantiomers in chronic social defeat stress (CSDS) model. NRBP1 was localized in the microglia and neuron, not astrocyte, of mouse medial prefrontal cortex (mPFC). (R)-ketamine increased the expression of NRBP1, brain-derived neurotrophic factor (BDNF), and phosphorylated cAMP response element binding protein (p-CREB)/CREB ratio in primary microglia cultures thorough the extracellular signal-regulated kinase (ERK) activation. Furthermore, (R)-ketamine could activate BDNF transcription through activation of CREB as well as MeCP2 (methyl-CpG binding protein 2) suppression in microglia. Single intracerebroventricular (i.c.v.) injection of CREB-DNA/RNA heteroduplex oligonucleotides (CREB-HDO) or BDNF exon IV-HDO blocked the antidepressant-like effects of (R)-ketamine in CSDS susceptible mice. Moreover, microglial depletion by colony-stimulating factor 1 receptor (CSF1R) inhibitor PLX3397 blocked the antidepressant-like effects of (R)-ketamine in CSDS susceptible mice. In addition, inhibition of microglia by single i.c.v. injection of mannosylated clodronate liposomes (MCLs) significantly blocked the antidepressant-like effects of (R)-ketamine in CSDS susceptible mice. Finally, single i.c.v. injection of CREB-HDO, BDNF exon IV-HDO or MCLs blocked the beneficial effects of (R)-ketamine on the reduced dendritic spine density in the mPFC of CSDS susceptible mice. These data suggest a novel ERK-NRBP1-CREB-BDNF pathways in microglia underlying antidepressant-like effects of (R)-ketamine.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
![Fig. 1 Effects of (R)-ketamine and (S)-ketamine on the BDNF activation. A, B The luciferase assay for BDNF exon IV promoter. A BDNF exon IV promoter activity in the HEK293T cells treated with (R)-ketamine (0.1, 1.0, and 10 μM) or (S)-ketamine (0.1, 1.0, and 10 μM). The data are the mean ± SEM (n = 6). **P < 0.01; ***P < 0.001 compared to vehicle group. $P < 0.05; $$P < 0.01; $$$P < 0.001 (one-way ANOVA). B BDNF exon IV promoter activity in the HEK293T cells treated with (R)-ketamine (10 μM) [or (S)-ketamine (10 μM)] with or without mutation (Mut) plasmids. The data are the mean ± SEM (n = 9 or 10). **P < 0.01; ***P < 0.001 (one-way ANOVA). C BDNF exon IV promoter activity in the HEK293T cells treated with (R)-ketamine (10 μM) with or without siRNA-CREB plasmids. The data are the mean ± SEM (n = 4). **P < 0.01; ***P < 0.001 (one-way ANOVA). D BDNF exon IV promoter activity in the HEK293T cells treated with (R)-ketamine (10 μM) with or without CREB-HDO or BDNF exon IV-HDO. The data are the mean ± SEM (n = 10). **P < 0.01; ***P < 0.001 (one-way ANOVA). E ChIP-PCR assay for BDNF IV promoter. The p-CREB protein–DNA crosslinking samples were obtained from the primary microglia treated with vehicle, (R)-ketamine (10 μM), or (S)-ketamine (10 μM) via co-immunoprecipitating with anti-p-CREB. PCR was carried out by using BDNF exon IV promoter primer. The data are the mean ± SEM (n = 4). *P < 0.05; ***P < 0.001 (one-way ANOVA). F The immunofluorescence for p-CREB and MeCP2 in the LPS (1 µg/mL)-treated primary microglia with (R)-ketamine (10 µM) or (S)-ketamine (10 µM). Scale bar = 50 μm. G Expression of NRBP1, BDNF, MeCP2, and the ratio of p-CREB/CREB in the LPS-treated primary microglia with (R)-ketamine (10 µM) or (S)-ketamine (10 µM). The data are the mean ± SEM (n = 5). *P < 0.05; **P < 0.01; ***P < 0.001 (one-way ANOVA).](https://figures.cochat.ai/paper-figures/34f3f7ee63654bae9addbb01b553d300/microglial-erk-nrbp1-creb-bdnf-signaling-in-sustained-antidepressant-actions-of-figure-1.jpg)




Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Studies using pharmacological inhibitors or genetic ablation models of microglia have demonstrated that the absence or inhibition of these cells completely abolishes the antidepressant effects of ketamine, emphasizing their essential role in the drug’s mechanism of action [81].”
From Variations in BDNF and Their Role in the Neurotrophic Antidepressant Mechanisms of Ketamine and Esketamine: A Review (2024) · cites this paper as [81]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“This phosphorylation is a key step in upregulating BDNF transcription, a pivotal factor in mediating synaptic plasticity and promoting resilience against stress-related depressive behaviors [81].”
From Variations in BDNF and Their Role in the Neurotrophic Antidepressant Mechanisms of Ketamine and Esketamine: A Review (2024) · cites this paper as [81]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Additionally, (R)-ketamine’s effect on microglia has been shown to involve suppression of pro-inflammatory mediators, such as interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-α), which contribute to neuroinflammation [81,83].”
From Variations in BDNF and Their Role in the Neurotrophic Antidepressant Mechanisms of Ketamine and Esketamine: A Review (2024) · cites this paper as [81]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“microglia (3) also play a role, with ketamine increasing the expression of Nuclear Receptor Binding Protein 1 (NRBP1) and phosphorylated cAMP response element-binding protein (CREB), leading to an increased transcription of BDNF.”
From Variations in BDNF and Their Role in the Neurotrophic Antidepressant Mechanisms of Ketamine and Esketamine: A Review (2024) · cites this paper as [81]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“This anti-inflammatory property of (R)-ketamine may enhance the functional role of microglia in supporting neuronal health, reducing oxidative stress, and promoting synaptic connectivity [81,83].”
From Variations in BDNF and Their Role in the Neurotrophic Antidepressant Mechanisms of Ketamine and Esketamine: A Review (2024) · cites this paper as [81]
Experimental — accuracy not yet measured
4 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Molecular Mechanisms of Depression: Perspectives on New Treatment Strategies
Lang, U. E., & Borgwardt, S. (2013) · Cellular Physiology and Biochemistry · doi:10.1159/000350094 · Cited by 8,475
Antidepressant effects of ketamine in depressed patients
Berman, R. M., Cappiello, A., Anand, A., Oren, D. A., Heninger, G. R., Charney, D. S., & Krystal, J. H. (2000) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00230-9 · Cited by 3,856 · cited 1×
“[5] reported rapid-acting and sustained antidepressant effects of (R,S)-ketamine in patients with depression.”
BackgroundA randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Zarate, C. A., Singh, J. B., Carlson, P. J., Brutsche, N. E., Ameli, R., Luckenbaugh, D. A., Charney, D. S., & Manji, H. K. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.8.856 · Cited by 3,766
Differential Roles of M1 and M2 Microglia in Neurodegenerative Diseases
Tang, Y., & Le, W. (2016) · Molecular Neurobiology · doi:10.1007/s12035-014-9070-5 · Cited by 2,190 · cited 1×
“Microglia can produce either cytotoxic or neuroprotective effects [67].”
BackgroundElmore, M. R. P., Najafi, A. R., Koike, M. A., Dagher, N. N., Spangenberg, E. E., Rice, R. A., Kitazawa, M., Matusow, B., Nguyen, H., West, B. L., et al. (2014) · Neuron · doi:10.1016/j.neuron.2014.02.040 · Cited by 1,968 · cited 1×
“Effect of microglia depletion on antidepressant-like effects of (R)-ketamine Activation of CSF1R is essential for survival in microglia [66].”
BackgroundNMDA receptor blockade at rest triggers rapid behavioural antidepressant responses
Autry, A. E., Adachi, M., Nosyreva, E., Na, E. S., Los, M. F., Cheng, P.-F., Kavalali, E. T., & Monteggia, L. M. (2011) · Nature · doi:10.1038/nature10130 · Cited by 1,926 · cited 1×
“In contrast, other brain regions such as hippocampus and nucleus accumbens are known to play a role in depression-like phenotypes [27, 41, 48, 50, 77, 78].”
BackgroundM2 microglia and macrophages drive oligodendrocyte differentiation during CNS remyelination
Miron, V. E., Boyd, A., Zhao, J.-W., Yuen, T. J., Ruckh, J. M., Shadrach, J. L., van Wijngaarden, P., Wagers, A. J., Williams, A., Franklin, R. J. M., et al. (2013) · Nature Neuroscience · doi:10.1038/nn.3469 · Cited by 1,777 · cited 2×
“S9), consistent with the previous report [68].”
Brain-derived neurotrophic factor produces antidepressant effects in behavioral models of depression
Shirayama, Y., Chen, A. C.-H., Nakagawa, S., Russell, D. S., & Duman, R. S. (2002) · The Journal of Neuroscience · doi:10.1523/jneurosci.22-08-03251.2002 · Cited by 1,654 · cited 1×
“[45] reported that direct injection of BDNF in the hippocampus caused long-lasting (i.”
BackgroundSynaptic Dysfunction in Depression: Potential Therapeutic Targets
Duman, R. S., & Aghajanian, G. K. (2012) · Science · doi:10.1126/science.1222939 · Cited by 1,651 · cited 2×
“Second, we selected mPFC of mouse brain since mPFC is implicated in depression-like phenotypes [27, 47, 48].”
MethodNMDAR inhibition-independent antidepressant actions of ketamine metabolites
Zanos, P., Moaddel, R., Morris, P. J., Georgiou, P., Fischell, J., Elmer, G. I., Alkondon, M., Yuan, P., Pribut, H. J., Singh, N. S., et al. (2016) · Nature · doi:10.1038/nature17998 · Cited by 1,609 · cited 1×
“In contrast, (2R,6R)HNK (the metabolite from (R)-ketamine) [28] did not activate Bdnf exon IV promoter whereas its parent compound (R)-ketamine significantly activated Bdnf exon IV promoter (Fig.”
Background
Cited by
Brain–gut–microbiota axis in depression: A historical overview and future directions
Chang, L., Wei, Y., & Hashimoto, K. (2022) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2022.02.004 · Cited by 377
Self-citationKetamine and rapid antidepressant action: New treatments and novel synaptic signaling mechanisms
Krystal, J. H., Kavalali, E. T., & Monteggia, L. M. (2024) · Neuropsychopharmacology · doi:10.1038/s41386-023-01629-w · Cited by 262
“Other proposed mechanisms for ketamine ’ s antidepressant action include ketamine enantiomers [10] and metabolites [11], the potential role of in fl ammatory processes [12], and non-neuronal contributions including those from microglia [13], among others.”
BackgroundThe molecular pathophysiology of depression and the new therapeutics
Tian, H., Hu, Z., Xu, J., & Wang, C. (2022) · MedComm · doi:10.1002/mco2.156 · Cited by 122
The antidepressant actions of ketamine and its enantiomers
Johnston, J. N., Henter, I. D., & Zarate, C. A. (2023) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2023.108431 · Cited by 118
Roles of microglia in adult hippocampal neurogenesis in depression and their therapeutics
Fang, S., Wu, Z., Guo, Y., Zhu, W., Wan, C., Yuan, N., Chen, J., Hao, W., Mo, X., Guo, X., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1193053 · Cited by 96
“Recently, our group found that (R)- ketamine exerts an antidepressant effect by inhibiting microglial ERK-NRBP1-CREB-BDNF signaling in the mPFC of CSDS mice, suggesting that the regulation of ketamine involves microglia and BDNF (230).”
BackgroundSelf-citation
Metadata
- Authors
- Yao, W., Cao, Q., Luo, S., He, L., Yang, C., Chen, J., Qi, Q., Hashimoto, K., & Zhang, J.-C.
- Affiliations
- Jinan University (CN)
- Central South University (CN)
- Chiba University (JP)
- Corresponding author
- Qi, Qi
- Hashimoto, Kenji
- Zhang, Ji-chun
- ORCID
- Venue
- Molecular Psychiatry
- Published
- 2021-11-24
- Volume
- 27
- Issue
- 3
- Pages
- 1618-1629
- ISSN
- 1359-4184 (ISSN-L)
- 1476-5578
- PMC
- PMC9095473
- OpenAlex
- W3216353063
- Cited by
- 216
- References
- 80
- Citations by year
- 2026: 29 · 2025: 44 · 2024: 56 · 2023: 50 · 2022: 36 · 2021: 1
- FWCI
- 18.94
- Type
- journal article
- Language
- en
- Update notices
- correction (2021-12-08)
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Molecular Psychiatry (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- MEXT | Japan Society for the Promotion of Science (21H02846, 24116006)
- National Natural Science Foundation of China (81973341)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Life Sciences › Neuroscience › Biological Psychiatry › Tryptophan and brain disorders
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Keywords
- (R)-ketamine, antidepressant effects, microglia, ERK signaling, NRBP1, CREB, brain-derived neurotrophic factor, chronic social defeat stress, depression, medial prefrontal cortex, MeCP2, microglial depletion, dendritic spine density, enantiomers, rapid-acting antidepressants
- MeSH terms
- Animals, Antidepressive Agents, Depression, Humans, Ketamine, Mice, Inbred C57BL, Stress, Psychological, Microglia, Receptors, Cytoplasmic and Nuclear, Brain-Derived Neurotrophic Factor, Vesicular Transport Proteins, Extracellular Signal-Regulated MAP Kinases, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Microglial ERK-NRBP1-CREB-BDNF signaling in sustained antidepressant actions of (R)-ketamine. https://app.cochat.ai/papers/10.1038/s41380-021-01377-7
- The paper
- Yao, W., Cao, Q., Luo, S., He, L., Yang, C., Chen, J., Qi, Q., Hashimoto, K., & Zhang, J.-C. (2022). Microglial ERK-NRBP1-CREB-BDNF signaling in sustained antidepressant actions of (R)-ketamine. Molecular Psychiatry. https://doi.org/10.1038/s41380-021-01377-7
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.